What does TYBOURNE CAPITAL MANAGEMENT (HK) LTD hold? Q3 2025 13F Holdings & Portfolio

AI Analysis · Q3 2025 · Q3 2025

TYBOURNE CAPITAL MANAGEMENT (HK) LTD filed its latest 13F-HR for Q3 2025. See the latest holdings and position changes below.

Quarter at a glance — Q3 2025

Position-change comparison pending.

No quarter-over-quarter changes available.

By portfolio weight as of Q3 2025.

#HoldingValueSharesWeight

TAYSHA GENE THERAPIES INC (TSHA US)

$12M3.7M39.1%

FORTE BIOSCIENCES INC (FBRX US)

$12M787K38.1%

ALUMIS INC (ALMS US)

$6M1.4M18.0%

ZENTALIS PHARMACEUTICALS INC (ZNTL US)

$1M961K4.7%

Filing history loading…